Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.65 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.65 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.65 |
| ▸ | ELANE | P08246 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2063502 | 0.93 | KMT2A (0.73) | RAB9ANPC1KMT2AMEN1LMNA | |
| SCHEMBL17570205 | 0.91 | KMT2A (0.70) | RAB9ANPC1KMT2AMEN1LMNA | |
| SCHEMBL2740446 | 0.89 | HSD17B10 (0.65) | RAB9ANPC1KMT2AMEN1LMNA | |
| SCHEMBL16681524 | 0.86 | TOP1 (0.66) | RAB9ANPC1KMT2AMEN1LMNA | |
| SCHEMBL7274228 | 0.85 | NPC1 (0.71) | RAB9ANPC1KMT2AMEN1LMNA | |
| SCHEMBL1232616 | 0.85 | KMT2A (0.62) | RAB9ANPC1KMT2AMEN1LMNA | |
| SCHEMBL12268804 | 0.85 | NPC1 (0.81) | RAB9ANPC1KMT2AMEN1LMNA | |
| SCHEMBL28107729 | 0.84 | ELANE (0.66) | RAB9ANPC1KMT2AMEN1PGR | |
| SCHEMBL16677946 | 0.84 | LMNA (0.72) | RAB9ANPC1KMT2AMEN1LMNA | |
| SCHEMBL6815598 | 0.84 | KMT2A (0.69) | RAB9ANPC1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| WO-2007126609-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| CN-1061041-C | Piperidine derivatives | GLAXO GROUP LTD (GB) | 2001-01-24 | — | — | CN | disclosed |
| CN-1155278-A | Arylthio compounds as antibacteral and antiviral agents | WARNER LAMBERT CO (US) | 1997-07-23 | — | — | CN | disclosed |
| CN-1135218-A | Piperidine derivatives | GLAXO GROUP LTD (GB) | 1996-11-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | RAB9A 2457/4885NPC1 849/4885KMT2A 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.